Monopar Regains Compliance with Nasdaq Minimum Bid Price Rule

Rhea-AI Summary

Monopar Therapeutics (Nasdaq: MNPR), a clinical-stage radiopharma company, has regained compliance with Nasdaq's minimum bid price requirement. The company received notice from Nasdaq that it has met the listing rule 5550(a)(2), which requires a minimum bid price of $1.00 per share for at least 10 consecutive trading sessions. This development ensures Monopar's continued listing on the Nasdaq stock exchange, maintaining its visibility and access to capital markets. The compliance status is important for the company's ongoing efforts in developing innovative cancer treatments.

Positive

• Regained compliance with Nasdaq's minimum bid price requirement
• Maintained listing on Nasdaq stock exchange
• Ensured continued visibility and access to capital markets

Negative

• None.

WILMETTE, Ill., Aug. 27, 2024 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage radiopharma company focused on developing innovative treatments for cancer patients, today announced that it received notice from The Nasdaq Stock Market LLC (Nasdaq) that it has regained compliance with the minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2) as a result of the closing bid price of the Company’s common stock being $1.00 per share or greater for 10 consecutive trading sessions. The Company is now compliant with the minimum bid price listing standard for continued Nasdaq listing.

About Monopar Therapeutics Inc. 

Monopar Therapeutics is a clinical-stage radiopharmaceutical company focused on developing innovative treatments for cancer patients, including Phase 1-stage MNPR-101-Zr for imaging advanced cancers, Phase 1-stage MNPR-101-Lu and late preclinical-stage MNPR-101-Ac225 for the treatment of advanced cancers, as well as early development stage programs against solid cancers. For more information, visit: www.monopartx.com.

CONTACT:

Monopar Therapeutics Inc.
Investor Relations
Karthik Radhakrishnan
Chief Financial Officer
karthik@monopartx.com

Follow Monopar on social media for updates:

Twitter: @MonoparTx LinkedIn: Monopar Therapeutics

FAQ

What Nasdaq rule did Monopar Therapeutics (MNPR) comply with on August 27, 2024?

Monopar Therapeutics complied with Nasdaq Listing Rule 5550(a)(2), which requires a minimum bid price of $1.00 per share for at least 10 consecutive trading sessions.

How long did Monopar Therapeutics (MNPR) maintain a closing bid price above $1.00 to regain compliance?

Monopar Therapeutics maintained a closing bid price of $1.00 or greater for 10 consecutive trading sessions to regain compliance with Nasdaq's minimum bid price requirement.

What is the impact of regaining Nasdaq compliance for Monopar Therapeutics (MNPR)?

Regaining Nasdaq compliance ensures Monopar Therapeutics' continued listing on the Nasdaq stock exchange, maintaining its visibility and access to capital markets, which is important for its ongoing efforts in developing innovative cancer treatments.